{"filing":{"accession_number":"0001104659-26-118519","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"tm2626240d4_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926118519/tm2626240d4_8k.htm"},"events":[{"id":37702,"run_id":34745,"accession_number":"0001104659-26-118519","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments establishing an at-the-market (ATM) offering facility allowing the Company to sell up to $50,000,000 in newly issued common stock over a 36-month period at a 6% discount to VWAP, with multiple purchase mechanisms and an unregistered private placement to accredited investors under Section 4(a)(2) and Rule 506(b) exemptions.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42494,"accession_number":"0001104659-26-118519","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments granting the Company the right to sell up to $50,000,000 in newly issued common stock at the Company's discretion over a 36-month period. This is a classic at-the-market (ATM) offering structure with multiple purchase mechanisms (Market Open, Intraday, Pre-Market, Post-Market Purchases), all priced at a 6% discount to VWAP. The agreement is material because it represents a significant dilutive equity issuance facility that could substantially increase share count and is typical of capital-raising activity by smaller public companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:19:39.261793+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42495,"accession_number":"0001104659-26-118519","item_number":"3.02","item_title":"Unregistered","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of Common Stock pursuant to a Purchase Agreement (referenced in Item 1.01), issued under Section 4(a)(2) and Rule 506(b) exemptions to accredited investors. This is a classic private placement of equity securities without public registration, which is material to investors as it represents potential dilution and capital raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:19:39.261793+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42494,"accession_number":"0001104659-26-118519","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments granting the Company the right to sell up to $50,000,000 in newly issued common stock at the Company's discretion over a 36-month period. This is a classic at-the-market (ATM) offering structure with multiple purchase mechanisms (Market Open, Intraday, Pre-Market, Post-Market Purchases), all priced at a 6% discount to VWAP. The agreement is material because it represents a significant dilutive equity issuance facility that could substantially increase share count and is typical of capital-raising activity by smaller public companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:19:39.261793+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-10-23"},{"id":42495,"accession_number":"0001104659-26-118519","item_number":"3.02","item_title":"Unregistered","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of Common Stock pursuant to a Purchase Agreement (referenced in Item 1.01), issued under Section 4(a)(2) and Rule 506(b) exemptions to accredited investors. This is a classic private placement of equity securities without public registration, which is material to investors as it represents potential dilution and capital raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:19:39.261793+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-10-23"}]}